Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Nabil K. Thalji, MD PhD, Prakash A Patel, MD, Rodney M. Camire, PhD

Blood (2019) 134 (Supplement_1): 3640.

https://doi.org/10.1182/blood-2019-125955

Published: 2019

Journal Articles

Protective Effects of Carbon Monoxide Delivered By Corm-401 in Hyperhemolysis in Patients with Sickle Cell Disease

Nguyen-Peyre Kim-Anh, PhD, Bodivit Gwellaouen, Foresti Roberta, PhD, Kiger Laurent, PhD, Gaetana Di Liberto, PhD, Philippe Chadebech, PhD, Alicia Jouard, Sadaf Pakdaman, Seguin Marion, Marden Micheal, PhD, France Pirenne, MD PhD, Motterlini Roberto, PhD, Pablo Bartolucci, MD PhD

Blood (2018) 132 (Supplement 1): 2367.

https://doi.org/10.1182/blood-2018-99-112900

Published: 2018

Journal Articles

Acquired Von Willebrand Factor Deficiency Caused By Left Ventricular Assist Devices Is Adamts-13 Dependent

Petra Jilma-Stohlawetz, MD, Schima Heinrich, PhD, Martin Stoiber, Peter Quehenberger, MD, Sabine Schranz, RN, Bernd Jilma, MD

Blood (2013) 122 (21): 3602.

https://doi.org/10.1182/blood.V122.21.3602.3602

Published: 2013

Journal Articles

A Novel Test for the Rapid Rule Out of Heparin-Induced Thrombocytopenia Diagnosis in Intensive Care unit patients

Vassiliki Galea, Francoise Robert, Patrick Van Dreden, Barry J Woodhams, Grigoris T Gerotziafas, Mohamed Hatmi, Ismail Elalamy

Blood (2012) 120 (21): 1119.

https://doi.org/10.1182/blood.V120.21.1119.1119

Published: 2012

Journal Articles

Excess Factor XIII (FXIII) Consumption During Cardiopulmonary Bypass Surgery in a Patient with Congenital FXIII Deficiency

Maissaa Janbain, MD, Cindy A. Leissinger, MD

Blood (2012) 120 (21): 4632.

https://doi.org/10.1182/blood.V120.21.4632.4632

Published: 2012

Journal Articles

Efficacy of Fondaparinux in the Treatment of Heparin-Induced Thrombocytopenia with Venous Thromboembolism: Reduction of Thromboembolic Burden, Normalization of Platelet Count and Disappearance of Anti-Platelet Factor 4/Heparin Antibodies.

Franco Piovella, MD, Marisa Barone, MD, Chiara Beltrametti, MD, Chiara Piovella, MD, Andrea M. D’Armini, MD, Federico Capra Marzani, MD, Vittorio Arici, MD, Mara De Amici, MD, Stefano L. Barco, MS, Gianluca Castellani, MD, Martin Langer, MD

Blood (2006) 108 (11): 575.

https://doi.org/10.1182/blood.V108.11.575.575

Published: 2006

Journal Articles

Argatroban for Anticoagulation during Cardiopulmonary Bypass.

Monte E. Martin, MD, Goetz H. Kloecker, MD, MSP.H., Anand Patel, MD, Damian A. Laber, MD, F.A.C.P.

Blood (2005) 106 (11): 4150.

https://doi.org/10.1182/blood.V106.11.4150.4150

Published: 2005

Journal Articles

The Determination of the Inhibitory Activity of Some Factor VIII Type II Inhibitor Antibodies Is Biased by the Type of Factor VIII Assay.

Marc G. Jacquemin, MD, Seb Lamprecht, MSc, Renaud Lavend’homme, MSc, Jan Roodt, MSc, Bernard Chatelain, MD, Veronique Deneys, MD, Jeroen Dewaele, MSc, Jean-Marie Stassen, PhD, Muriel Meiring, PhD, Jean Marie Saint-Remy, MD, Henry Pieters, PhD, Philip Badenhorst, MD

Blood (2005) 106 (11): 3200.

https://doi.org/10.1182/blood.V106.11.3200.3200

Published: 2005

Journal Articles

Antithrombotic Effects of Concomitant Administration of BAY 59–7939 with Enoxaparin or Heparin - Interaction Study.

Elisabeth Perzborn, PhD, Brigitte Arndt

Blood (2004) 104 (11): 1863.

https://doi.org/10.1182/blood.V104.11.1863.1863

Published: 2004

Journal Articles

Compstatin Inhibits Complement and Cellular Activation in Whole Blood in Two Models of Extracorporeal Circulation

Bo Nilsson, Rolf Larsson, Jaan Hong, Graciela Elgue, Kristina Nilsson Ekdahl, Arvind Sahu, John D. Lambris

Blood (1998) 92 (5): 1661–1667.

https://doi.org/10.1182/blood.V92.5.1661

Published: 1998

NARROW

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Protective Effects of Carbon Monoxide Delivered By Corm-401 in Hyperhemolysis in Patients with Sickle Cell Disease

Acquired Von Willebrand Factor Deficiency Caused By Left Ventricular Assist Devices Is Adamts-13 Dependent

A Novel Test for the Rapid Rule Out of Heparin-Induced Thrombocytopenia Diagnosis in Intensive Care unit patients

Excess Factor XIII (FXIII) Consumption During Cardiopulmonary Bypass Surgery in a Patient with Congenital FXIII Deficiency

Efficacy of Fondaparinux in the Treatment of Heparin-Induced Thrombocytopenia with Venous Thromboembolism: Reduction of Thromboembolic Burden, Normalization of Platelet Count and Disappearance of Anti-Platelet Factor 4/Heparin Antibodies.

Argatroban for Anticoagulation during Cardiopulmonary Bypass.

The Determination of the Inhibitory Activity of Some Factor VIII Type II Inhibitor Antibodies Is Biased by the Type of Factor VIII Assay.

Antithrombotic Effects of Concomitant Administration of BAY 59–7939 with Enoxaparin or Heparin - Interaction Study.

Compstatin Inhibits Complement and Cellular Activation in Whole Blood in Two Models of Extracorporeal Circulation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only